Non-alcoholic fatty liver – Perhaps not so benign  by Adams, Leon A. & Ratziu, Vlad
EditorialNon-alcoholic fatty liver – Perhaps not so benign
Leon A. Adams1, Vlad Ratziu2,⇑
1School of Medicine and Pharmacology, The University of Western Australia, Nedlands, Australia; 2Université Pierre et Marie Curie, Institute for
Cardiometabolism and Nutrition, Hospital Pitié Salpêtrière, Paris, FranceSee Article pages 1148–1155The deﬁning histological feature of non-alcoholic fatty liver
disease (NAFLD) is lipid droplets within hepatocytes. There are
however, a range of histological changes that may accompany
hepatic steatosis including combinations of lobular and/or portal
inﬂammation, hepatocyte ballooning and ﬁbrosis. The sig-
niﬁcance of these accompanying histological changes, is that they
help deﬁne the clinical course of the patient. Early studies
demonstrated a dichotomy in outcomes based upon the presence
or absence of non-alcoholic steatohepatitis (NASH). Follow-up of
patients with biopsy proven hepatic steatosis without inﬂamma-
tion or ballooning (termed ‘bland steatosis’), reveals a remarkably
benign course with very few individuals progressing to cirrhosis
or dying from liver disease [1,2]. In contrast, patients with bal-
looning, Mallory hyaline or ﬁbrosis (i.e. NASH) are more likely
to progress to cirrhosis and die from its complications [3,4].
Accordingly, the current management guidelines for NAFLD
revolve around determining the presence or absence of NASH.
In the presence of NASH, liver speciﬁc pharmacotherapy should
be considered in addition to lifestyle changes involving weight
loss and exercise [5,6]. If NASH is excluded, then lifestyle inter-
ventions alone are recommended. This paradigm suggests that
patients with bland steatosis or steatosis with non-speciﬁc
inﬂammation (collectively termed non-alcoholic fatty liver or
NAFL) do not develop a ‘second pathological hit’ and remain
within the same histological spectrum of disease over time.
Although this notion was challenged 10 years ago [7], there is a
paucity of knowledge regarding whether non-NASH (a.k.a.
NAFL) can progress and thus acquire the prognostic and manage-
ment implications that are associated with NASH.
Two studies published in the Journal of Hepatology have pro-
vided further insight into the natural history of NAFLD and
challenge the dogma that NAFL is non-progressive. In this issue,
McPherson and colleagues carefully evaluated 108 patients with
NAFLD who underwent paired liver biopsies over a medianJournal of Hepatology 20
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Open access under CC BY-NC-ND license.interval of 6.6 years [21]. Twenty-seven of the 108 patients that
had NAFL (steatosis alone or with mild inﬂammation), 10 (37%)
developed ﬁbrosis, with 6 (22%) of these having bridging ﬁbrosis
on follow-up biopsy. Interestingly, the proportion of patients who
had progressive ﬁbrosis was not different between patients who
had NAFL or NASH (37% vs. 43%, p = 0.6). In a previous issue of the
Journal, Pais et al. described a similar phenomena in a cohort of 70
NAFLD patients who underwent paired liver biopsies; among 25
subjects with NAFL at baseline, 16/25 (64%) progressed to NASH
and 6 (24%) developed bridging ﬁbrosis over a mean of 3.7 years
[8]. Thus collectively, these studies suggest that NAFL may clearly
progress, with one quarter of patients developing bridging
ﬁbrosis over a relatively short time period.
This data needs to be treated with some caution as there are
clear limitations and caveats to studies where subjects have
undergone serial liver biopsies. Although a proportion of fol-
low-up biopsies may be performed as part of clinical trials, they
are generally performed for clinical reasons such as suspicion of
progressive disease, thereby creating bias. Furthermore, sampling
error with liver biopsies leads to the possibility of misclassiﬁca-
tion, as does variability in pathologist interpretation which is par-
ticularly problematic for features such as inﬂammation and
ballooning [9]. Therefore larger numbers to overcome the
variance associated with sampling error, and robust histological
evaluation and classiﬁcation will be required for future studies.
While keeping in mind the heterogeneity of distribution of
histological lesions in NAFLD, two of the results from the
British study are striking. First, eight out of 10 patients with
steatosis and non-speciﬁc inﬂammation evolved towards full-
blown steatohepatitis, while only 2 regressed towards bland
steatosis. While this might still be due to sampling variability,
it may more likely reﬂect a real trend in disease progression.
Equally striking is the rate of spontaneous NASH resolution: only
six of 81 patients with steatohepatitis at baseline no longer had
steatohepatitis at follow-up. Whether one or several of these 6
patients actually improved their metabolic condition in between
biopsies thus explaining the clearance of steatohepatitis is
unknown. Yet, this very low ﬁgure stresses the ‘‘stability’’ of
steatohepatitis as a pathological ﬁnding in the absence of
therapeutic intervention. It thus strengthens ‘‘resolution
of NASH’’ as a non-labile surrogate outcome for clinical trials in
general and pivotal registration studies in particular [10,11].15 vol. 62 j 1002–1004
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The probability that NASH resolves as a chance ﬁnding appears to
be very low.
Although these studies have demonstrated progressive liver
injury among subjects with NAFL, how do we reconcile these
paired biopsy studies with the benign outcomes for NAFL
patients from longitudinal cohort studies previously mentioned?
Are these patients actually at risk of liver related morbidity and
mortality? The risk is clearly low but not negligible, with up to
6% of subjects with bland steatosis dying from liver disease over
8–20 years of follow-up. It is notable that the average age of these
cohorts was between 40–50 years at baseline. Although it is
unknown when these individuals acquired NAFLD, we do know
that currently one in seven adolescents have NAFLD in developed
countries [12]. Thus these adolescents will potentially have ﬁve
or more decades of ‘exposure’ to NAFL. Assuming the risk of pro-
gressive liver disease is time-dependent, the burden of end-stage
liver disease associated with NAFL could be substantial.
If progressive liver ﬁbrosis can occur across the entire histo-
logical spectrum of NAFLD, are we able to predict patients who
will progress? A variety of features associated with NASH
including necro-inﬂammation, ballooning and Mallory-Denk
bodies have been associated with progressive ﬁbrosis or a higher
ﬁbrosis progression rate in systematic reviews as well as a large
series from the NASH CRN, published in abstract form [13–15].
Although these cohorts have included predominantly NASH
patients, it appears inﬂammation may also be associated with a
differential rate of histological progression within the spectrum
of NAFL. Within the McPherson and Pais cohorts, subjects with
bland steatosis were less likely to develop NASH or progressive
ﬁbrosis than those with steatosis and mild inﬂammation.
Although these differences were not statistically signiﬁcant in
either study due to the low numbers, this gradient of risk has also
been noted in other cohorts [16,17]. Therefore, liver mortality
rates for NAFL subjects with mild inﬂammation may be higher
than those with bland steatosis. Furthermore, when McPherson
and colleagues looked at just NAFL subjects, baseline steatosis
grade was higher in those with progressive ﬁbrosis, suggesting
the prognostic importance of different histological features may
differ according to the stage of liver disease.
Unfortunately, baseline clinical parameters have limited uti-
lity in predicting patients who will have progressive disease. In
the McPherson study, the biochemical algorithm FIB-4
(composed of age, AST, ALT, and platelet count) was higher
among subjects who had progressive ﬁbrosis, although its accura-
cy to predict these individuals remained poor. However, both
studies demonstrated that body weight and diabetes prevalence
increased in parallel with progressive liver injury. Thus subjects
with evidence of liver injury and inﬂammation and perhaps sev-
ere steatosis in the case of NAFL, are at greater risk of histological
progression, as are those with worsening metabolic disease.
Interestingly, this latter point is corroborated by a large series
of 270 early-stage NAFLD patients (stages 0 to 2) with follow-
up liver biopsies collected by the NASH CRN [18]. Fibrosis pro-
gression towards bridging ﬁbrosis occurred in 16% over a median
of 4.4 years. Crude predictors of progression were type 2 diabetes,
the metabolic syndrome, a high HOMA score indicative of insulin
resistance. Collectively, those converging observations are impor-
tant because the metabolic state of a patient can be monitored.
Persistence or worsening of metabolic risk factors should alert
us to the possibility of disease progression. The current studies
suggest that this also applies to patients with early diseaseJournal of Hepatology 2015including NAFL. A closer follow-up of this subset of NAFL
individuals is therefore legitimate and should focus on detecting
disease progression, either by non-invasive procedures or by liver
biopsy. This is clearly different from current patterns of practice.
How do we translate these ﬁndings to the large proportion of
the population who have NAFLD? Although this data suggests all
NAFLD patients are at potential risk of progressive liver disease
over a long period, recent studies have shown that ﬁbrosis remains
the best histological predictor of liver related complications and
overall death [19,20]. In the largest series to date presented in
abstract form, stages 2–4 ﬁbrosis were the only histological
features predictive of cirrhosis related complications in 619 indi-
viduals followed for a median of 12.7 years [20]. Thus overall,
NAFLD is slowly progressive and the majority of individuals will
not progress to cirrhosis or liver related death. Nevertheless,
among patients with NAFL, which was previously considered to
be benign, approximately one quarter may develop liver ﬁbrosis.
The development of ﬁbrosis heralds an increased risk of morbidity
associatedwith cirrhosis and death. The challenge remains how to
best identify these patients and effectively treat them.
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